News

Menu
CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
May 28, 2020
Interim results showed Auxora plus standard of care improved time to recovery and reduced ventilator use in patients compared to standard of care alone LA …
CalciMedica Announces that FDA Has Strongly Recommended Moving to a Blinded Placebo-controlled Trial with Auxora™ in Patients with Severe COVID-19 Pneumonia
May 21, 2020
LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …
CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy
May 7, 2020
LA JOLLA, Calif., May 7, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …